Juno Tells Fed. Circ. To Uphold Its $1.2B Patent Win Over Kite
Law360 (December 15, 2020, 9:10 PM EST) -- Because Kite Pharma Inc. "brazenly chose" to infringe a cancer treatment patent with its Yescarta treatment, the Federal Circuit should not undo a lower court's $1.2 billion decision against it, Juno Therapeutics Inc. said Monday.
In its brief, Juno and the Sloan Kettering Institute for Cancer Research said the Federal Circuit should affirm a California federal court's decision to award them $1.2 billion after a jury found that Gilead unit Kite Pharma Inc. willfully infringed Juno's patent for a cancer immunotherapy.
Juno and Sloan Kettering said that "Kite brazenly chose infringement" after it failed to get around the patent at issue....
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!